{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T02:53:58Z","timestamp":1781751238915,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012921","name":"Royal College of Surgeons in Ireland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Magnetic resonance imaging (MR) of the prostate is an important part of the diagnostic pathway for patients with suspected prostate cancer. Current practice in many Irish centres is to perform biparametric MRI (bpMRI) incorporating T2- and diffusion-weighted imaging, and interpret it using the latest version of the American College of Radiology Prostate Imaging Reporting and Data System (PI-RADS), version 2.1. No study has yet reported on the use of bp-MRI and PI-RADS 2.1 in the investigation of prostate cancer investigation in the Irish healthcare setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We aimed to review one year of practice at our regional tertiary prostate cancer referral centre and compare diagnostic yield with international standards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified all patients who had undergone prostate biopsy at our institution in 2023 and extracted pre-biopsy MRI results for each patient, comparing MRI results with biopsy reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 328 patients in the study period who underwent prostate biopsy and pre-biopsy MRI. 182 of these had a pathological diagnosis of clinically significant prostate cancer (csPCa), defined as Gleason score of 7 or higher. Of these, 167 (92%) had a PI-RADS score of 3 or above, meaning at least equivocal for the presence of csPCA. Cancer detection rates were 31%, 54% and 96% for PI-RADS three, four and five lesions respectively. We demonstrated a sensitivity of 92% and specificity of 49% for detection of csPCa, closely aligned with international datasets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use and performance of bpMRI and PI-RADS 2.1 at our Irish tertiary urological centre is in line with international datasets. These have a key role in the diagnostic pathway of prostate cancer in Ireland.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11845-026-04469-x","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T02:37:00Z","timestamp":1781750220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PI-RADS 2.1 is valid for detecting prostate cancer in bpMRI in an Irish population"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-945X","authenticated-orcid":false,"given":"Patrick A.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesa Samuel","family":"Karunadhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Moynagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Janquli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutaz","family":"Nur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1draig J.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciar\u00e1n E.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"4469_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4469_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvi\u00e8re O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 79:243\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","journal-title":"Eur Urol"},{"key":"4469_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1","journal-title":"Lancet"},{"key":"4469_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Bud\u00e4us L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM (2018) MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 378:1767\u20131777. https:\/\/doi.org\/10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"key":"4469_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.mpdhp.2019.07.001","volume":"25","author":"E Short","year":"2019","unstructured":"Short E, Warren AY, Varma M (2019) Gleason grading of prostate cancer: a pragmatic approach. Diagn Histopathology 25:371\u2013378. https:\/\/doi.org\/https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.mpdhp.2019.07.001","journal-title":"Diagn Histopathology"},{"key":"4469_CR6","doi-asserted-by":"publisher","unstructured":"van Leenders G, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, Litjens G, McKenney JK, Melamed J, Mottet N, Paner GP, Samaratunga H, Schoots IG, Simko JP, Tsuzuki T, Varma M, Warren AY, Wheeler TM, Williamson SR, Iczkowski KA (2020) The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 44:e87\u2013e99. https:\/\/doi.org\/10.1097\/pas.0000000000001497","DOI":"10.1097\/pas.0000000000001497"},{"key":"4469_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/bju.12536","volume":"114","author":"JP Grummet","year":"2014","unstructured":"Grummet JP, Weerakoon M, Huang S, Lawrentschuk N, Frydenberg M, Moon DA, O\u2019Reilly M, Murphy D (2014) Sepsis and \u2018superbugs\u2019: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int 114:384\u2013388. https:\/\/doi.org\/10.1111\/bju.12536","journal-title":"BJU Int"},{"key":"4469_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/pcan.2015.29","volume":"18","author":"JP Radtke","year":"2015","unstructured":"Radtke JP, Boxler S, Kuru TH, Wolf MB, Alt CD, Popeneciu IV, Steinemann S, Huettenbrink C, Bergstraesser-Gasch C, Klein T, Kesch C, Roethke M, Becker N, Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA (2015) Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance. Prostate Cancer Prostatic Dis 18:288\u2013296. https:\/\/doi.org\/10.1038\/pcan.2015.29","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4469_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.21037\/tau.2017.03.58","volume":"6","author":"J Grummet","year":"2017","unstructured":"Grummet J, Pepdjonovic L, Huang S, Anderson E, Hadaschik B (2017) Transperineal vs. transrectal biopsy in MRI targeting. Transl Androl Urol 6:368\u2013375. https:\/\/doi.org\/10.21037\/tau.2017.03.58","journal-title":"Transl Androl Urol"},{"key":"4469_CR10","doi-asserted-by":"publisher","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340-351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"4469_CR11","doi-asserted-by":"publisher","first-page":"175628722210963","DOI":"10.1177\/17562872221096377","volume":"14","author":"JW Greenberg","year":"2022","unstructured":"Greenberg JW, Koller CR, Casado C, Triche BL, Krane LS (2022) A narrative review of biparametric MRI (bpMRI) implementation on screening, detection, and the overall accuracy for prostate cancer. Ther Adv Urol 14:17562872221096377. https:\/\/doi.org\/10.1177\/17562872221096377","journal-title":"Ther Adv Urol"},{"key":"4469_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00261-022-03750-8","volume":"48","author":"J Song","year":"2022","unstructured":"Song J, Zhao C, Zhang F, Yuan Y, Wang L, Sah V, Zhang J, Weng W, Yang Z, Wang Z, Wang L (2022) The diagnostic performance in clinically significant prostate cancer with PI-RADS version 2.1: simplified bpMRI versus standard mpMRI. Abdom Radiol 48:1\u20139. https:\/\/doi.org\/10.1007\/s00261-022-03750-8","journal-title":"Abdom Radiol"},{"key":"4469_CR13","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.24.32328","author":"E Salinas-Miranda","year":"2025","unstructured":"Salinas-Miranda E, Birosh A, McInnes MDF, Breau RH, Lam E, McGrath TA, Flood TA, Schieda N (2025) NPV of Biparametric and Multiparametric Prostate MRI: A Comparative Systematic Review and Meta-Analysis. AJR Am J Roentgenol. https:\/\/doi.org\/10.2214\/ajr.24.32328","journal-title":"AJR Am J Roentgenol"},{"key":"4469_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2214\/ajr.18.20103","volume":"212","author":"Z Kang","year":"2019","unstructured":"Kang Z, Min X, Weinreb J, Li Q, Feng Z, Wang L (2019) Abbreviated Biparametric Versus Standard Multiparametric MRI for Diagnosis of Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol 212:357\u2013365. https:\/\/doi.org\/10.2214\/ajr.18.20103","journal-title":"AJR Am J Roentgenol"},{"key":"4469_CR15","unstructured":"Oxley J, Colling R, Manohar V, Mitchard J (2024) Dataset for histopathology reports for prostatic carcinoma. Standards and datasets for reporting cancers. Royal College of Pathologists Guideline, RCPath, England"},{"key":"4469_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41391-021-00417-1","volume":"25","author":"B Oerther","year":"2022","unstructured":"Oerther B, Engel H, Bamberg F, Sigle A, Gratzke C, Benndorf M (2022) Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis 25:256\u2013263. https:\/\/doi.org\/10.1038\/s41391-021-00417-1","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4469_CR17","volume-title":"HSE National Clinical Guideline: Diagnosis and staging of patients with Prostate Cancer","author":"NCC Programme","year":"2024","unstructured":"Programme NCC (2024) HSE National Clinical Guideline: Diagnosis and staging of patients with Prostate Cancer. HSE National Clinical Guideline. HSE, Ireland"},{"key":"4469_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/jmri.28994","volume":"59","author":"YV Chaban","year":"2024","unstructured":"Chaban YV, Vosshenrich J, McKee H, Gunasekaran S, Brown MJ, Atalay MK, Heye T, Markl M, Woolen SA, Simonetti OP, Hanneman K (2024) Environmental Sustainability and MRI: Challenges, Opportunities, and a Call for Action. J Magn Reson Imaging 59:1149\u20131167. https:\/\/doi.org\/10.1002\/jmri.28994","journal-title":"J Magn Reson Imaging"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04469-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-026-04469-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-026-04469-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T02:37:04Z","timestamp":1781750224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-026-04469-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":18,"alternative-id":["4469"],"URL":"https:\/\/doi.org\/10.1007\/s11845-026-04469-x","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}